To further understand the role of HER4 in trastuzumab-treated HER2 positive breast cancer cell lines, we performed HER4 knockdown by transient transfection with specific HER4 siRNAs, with or without trastuzumab treatment. This evidence concerns the gene ERBB2 and breast cancer.